



ALK
Investor Relations Department
BÅge Alle 6-8
Horsholm DK-2970
Denmark

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

OMX: ALKB

Last Trade:	742.00
Trade Time:	4:59 PM ET Mar 16, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	646.00 - 1133.00
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

Company releases [\[View all \]](#)

Mar 16, 2018

[Articles of Association](#)

Mar 12, 2018

[Annual General Meeting in ALK-Abelló A/S held on 12 March 2018](#)

Mar 2, 2018

[Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer](#)

Mar 2, 2018

[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)

Feb 21, 2018

[New medicine for house dust mite allergic rhinitis and allergic asthma now available in France](#)

Upcoming Events [\[View all \]](#)

May 4, 2018

[Three-month interim report \(Q1\) 2018](#)

Aug 15, 2018

[Six-month interim report \(Q2\) 2018](#)